INQOVI (oral decitabine)

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Leukemia, Myelomonocytic, ChronicMyelodysplastic Syndrome (MDS)Myelodysplastic Syndromes

Phase 2

STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

TerminatedNCT04878432

Novartis PharmaceuticalsMyelodysplastic Syndrome (MDS)

Start: 2022-03-17End: 2024-09-01Updated: 2025-10-16

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

Active, not recruitingNCT05201066

Novartis PharmaceuticalsLeukemia, Myelomonocytic, Chronic, Myelodysplastic Syndromes

Start: 2023-02-13End: 2028-02-14Updated: 2026-01-07

Related Papers

TP53 in MDS & AML

Oncology Times2024-01-01

Sabatolimab in Combination with Hypomethylating Agents (HMAs) Was Safe in Patients (Pts) with Intermediate-, High-, or Very-High-Risk Myelodysplastic Syndrome (MDS)

Blood2023-11-021 citations

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Blood2022-11-153 citations

P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM

HemaSphere2022-06-011 citations

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Blood2021-11-0512 citations